静脉溶栓在血管内取栓前的角色
综述评估直接取栓与静脉溶栓后取栓的6项随机试验证据。试验多使用阿替普酶而非替奈普酶,仅适用于可直接取栓的医院就诊患者。总体功能结局相似,桥接溶栓组最终再灌注显著增加、症状性出血约增加1.8%、死亡非显著降低。作者认为在个体患者数据Meta分析前,静脉溶栓联合取栓仍保留重要作用。
要点
- 6项随机试验比较直接取栓与静脉溶栓后取栓,多使用阿替普酶。
- 桥接溶栓组最终再灌注显著增加,症状性出血约增加1.8%。
- 两组功能结局相似,死亡在桥接组非显著降低。
核心结论
- 作者认为在个体患者数据Meta分析结果出来前,静脉溶栓联合血管内取栓仍保留重要作用。
- 作者指出需进一步努力加速和增强溶栓再灌注,并进行个体患者水平汇总亚组分析。
研究设计与样本
- 综述评估6项直接取栓与静脉溶栓后取栓随机试验的证据及对临床实践的意义。
- 除一项试验中少数患者外,所有试验均使用阿替普酶而非替奈普酶。
- 这些试验仅适用于直接到有取栓能力医院就诊的患者,不适用于溶栓后转运至有取栓能力医院的患者。
主要发现
- 6项试验中2项达到预设非劣效界值,但该界值相对阿替普酶的绝对获益较大。
- 总体功能结局相似,轻微趋势 favoring 桥接溶栓,最终再灌注显著增加。
- 桥接溶栓组症状性出血约增加1.8%,死亡非显著降低。
- 直接取栓试验的流程为:先确认取栓和试验资格并完成随机化后再延迟给予溶栓,与标准实践相比减少了取栓前溶栓起效的时间。
临床怎么用
- 作者认为静脉溶栓联合血管内取栓仍保留重要作用,但需等待个体患者数据Meta分析。
局限性
- 除一项试验中少数患者外,所有试验均使用阿替普酶而非可能更有效的替奈普酶。
- 这些试验仅适用于直接到有取栓能力医院就诊的患者,不适用于溶栓后转运至有取栓能力医院的患者。
- 2项达到非劣效界值的试验,其界值相对阿替普酶的绝对获益较大。
- 直接取栓试验中延迟溶栓的流程减少了取栓前溶栓起效的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous thrombolytics and endovascular thrombectomy for ischemic stroke have evolved in parallel. However, the best approach to combine these reperfusion therapies in patients eligible for both strategies remains uncertain. Initial randomized trials of endovascular thrombectomy included administration of intravenous thrombolytics to all eligible patients. However, whether that is of net benefit has been questioned and parallels drawn with treatment of ST-segment-elevation myocardial infarction, where intravenous thrombolytics are only given if first medical contact to percutaneous intervention is expected to be >90 minutes. Six randomized trials of a direct thrombectomy approach versus intravenous thrombolytics followed by endovascular thrombectomy have now reported their results. With exception of a minority of patients in one trial, the trials all used alteplase rather than potentially more effective tenecteplase. This review examines the current state of evidence and implications for clinical practice. Importantly, these trials only apply to patients who present to a hospital with immediate access to endovascular thrombectomy and are not relevant to patients who receive thrombolytic and are then transferred to an endovascular-capable hospital. Although 2 of the 6 randomized trials met their prespecified noninferiority margin, these margins were large compared with the absolute benefit of alteplase. Overall, functional outcome was similar, with slight trends favoring bridging thrombolytics and a significant increase in final reperfusion. Symptomatic hemorrhage was increased by ≈1.8% in the bridging group but death was nonsignificantly lower. The workflow in direct thrombectomy trials involved delaying thrombolytic administration until eligibility for thrombectomy and the trials was established and randomization completed. This reduced the time available for thrombolytics to occur prethrombectomy compared with standard practice. We conclude that, pending individual-patient data meta-analyses, intravenous thrombolytics retain an important role alongside endovascular thrombectomy. Further efforts to accelerate and enhance reperfusion with thrombolytics and perform individual patient-level pooled subgroup analyses are warranted.
引用
- Campbell BCV, Kappelhof M, Fischer U, et al. Role of Intravenous Thrombolytics Prior to Endovascular Thrombectomy. Stroke. 2022. PMID: 35354294. doi:10.1161/STROKEAHA.122.036929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。